These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16251248)

  • 1. Protecting calcium and phosphate balance in chronic renal disease.
    McCarron DA
    J Am Soc Nephrol; 2005 Nov; 16 Suppl 2():S93-4. PubMed ID: 16251248
    [No Abstract]   [Full Text] [Related]  

  • 2. Dietary and pharmacological control of calcium and phosphate metabolism in predialysis stages of chronic kidney disease.
    Ketteler M; Biggar PH
    Blood Purif; 2009; 27(4):345-9. PubMed ID: 19295197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging role of a phosphatonin in mineral homeostasis and its derangements.
    Bielesz B
    Eur J Clin Invest; 2006 Aug; 36 Suppl 2():34-42. PubMed ID: 16884396
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of fibroblast growth factor 23 in renal disease.
    Jonsson KB
    Nephrol Dial Transplant; 2005 Mar; 20(3):479-82. PubMed ID: 15735238
    [No Abstract]   [Full Text] [Related]  

  • 5. Pathophysiology of calcium and phosphate metabolism impairment in chronic kidney disease.
    Cozzolino M; Ciceri P; Volpi EM; Olivi L; Messa PG
    Blood Purif; 2009; 27(4):338-44. PubMed ID: 19295196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulatory mechanisms of circulating fibroblast growth factor 23 in parathyroid diseases.
    Imanishi Y; Kobayashi K; Kawata T; Inaba M; Nishizawa Y
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S32-7. PubMed ID: 17976083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study.
    Fliser D; Kollerits B; Neyer U; Ankerst DP; Lhotta K; Lingenhel A; Ritz E; Kronenberg F; ; Kuen E; König P; Kraatz G; Mann JF; Müller GA; Köhler H; Riegler P
    J Am Soc Nephrol; 2007 Sep; 18(9):2600-8. PubMed ID: 17656479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [How Vitamin D Does control serum calcium and calcium balance? What are the characteristics of renal disease?].
    Jean G
    Nephrol Ther; 2013 Jun; 9(3):185-8. PubMed ID: 23719175
    [No Abstract]   [Full Text] [Related]  

  • 9. [Calcium-phosphate metabolism in kidney diseases].
    Krauz A
    Pol Tyg Lek; 1969 Dec; 24(49):1905-8. PubMed ID: 5369046
    [No Abstract]   [Full Text] [Related]  

  • 10. The bone-renal axis in early chronic kidney disease: an emerging paradigm.
    Danziger J
    Nephrol Dial Transplant; 2008 Sep; 23(9):2733-7. PubMed ID: 18469306
    [No Abstract]   [Full Text] [Related]  

  • 11. [Chronic kidney disease (CKD) and bone. Targets of serum calcium, phosphate, and parathyroid hormone levels and their controls in maintenance dialysis patients].
    Akiba T
    Clin Calcium; 2009 Apr; 19(4):537-44. PubMed ID: 19329833
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Chronic kidney disease (CKD) and bone. Management of chronic kidney disease-mineral and bone disorder in peritoneal dialysis patients].
    Yaginuma T; Yamamoto H
    Clin Calcium; 2009 Apr; 19(4):508-13. PubMed ID: 19329829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mineral metabolism and mortality in patients with chronic kidney disease.
    Young EW
    Adv Chronic Kidney Dis; 2007 Jan; 14(1):13-21. PubMed ID: 17200039
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Renal homeostasis of calcium.
    Yucha C; Guthrie D
    Nephrol Nurs J; 2003 Dec; 30(6):621-6; quiz 627-8. PubMed ID: 14730782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of megalin, a proximal tubular endocytic receptor, in calcium and phosphate homeostasis.
    Saito A; Iino N; Takeda T; Gejyo F
    Ther Apher Dial; 2007 Oct; 11 Suppl 1():S23-6. PubMed ID: 17976080
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of disturbances of calcium and phosphate metabolism on vascular calcification and clinical outcomes in patients with chronic kidney disease.
    Nikolov IG; Mozar A; Drüeke TB; Massy ZA
    Blood Purif; 2009; 27(4):350-9. PubMed ID: 19295198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sevelamer versus calcium-based phosphate binders in chronic kidney disease: what should we conclude from the evidence to date?
    Johnson DW
    Nephrol Dial Transplant; 2009 Oct; 24(10):2970-2. PubMed ID: 19633092
    [No Abstract]   [Full Text] [Related]  

  • 19. Mineral metabolism parameters throughout chronic kidney disease stages 1-5--achievement of K/DOQI target ranges.
    Craver L; Marco MP; Martínez I; Rue M; Borràs M; Martín ML; Sarró F; Valdivielso JM; Fernández E
    Nephrol Dial Transplant; 2007 Apr; 22(4):1171-6. PubMed ID: 17205962
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vascular changes in chronic renal disease patients with secondary hyperparathyroidism.
    Bortotolotto LA; Costa-Hong V; Jorgetti V; Consolim-Colombo F; Rosa K; Silva BC; Krieger EM; De Lima JJ
    J Nephrol; 2007; 20(1):66-72. PubMed ID: 17347976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.